Heparin modifies the immunogenicity of positively charged proteins

Blood

Volumn 116, Issue 26, 2010, Pages 6046-6053

  Chudasama, Shalini L ^a   Espinasse, Benjamin ^a   Hwang, Fred ^a   Qi, Rui ^a   Joglekar, Manali ^a   Afonina, Galyna ^a   Wiesner, Mark R ^a   Welsby, Ian J ^b   Ortel, Thomas L ^a   Arepally, Gowthami M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; INTERLEUKIN 12; LYSOZYME; PROTAMINE; THROMBOCYTE FACTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG PROTEIN BINDING; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 78650644854     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-292938     Document Type: Article

References (46)

1. Bock PE, Luscombe M, Marshall SE, Pepper DS, Holbrook JJ. The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J. 1980;191(3):769-776.
2. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71(2):247-251.
3. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood. 2005;105(1):131-138.
4. Greinacher A, Gopinadhan M, Gunther J-U, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol. 2006;26(10):2386-2393.
5. Suvarna S, Espinasse B, Qi R, et al. Determinants of PF4/heparin immunogenicity. Blood. 2007;110(13):4253-4260.
6. Suvarna S, Qi R, Arepally G. Optimization of a murine immunization model for study of PF4/heparin antibodies. J Thromb Haemost. 2009;7(5):857-864.
7. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl. 2002;41(3):391-412.
8. Mulloy B, Linhardt RJ. Order out of complexity-protein structures that interact with heparin. Curr Opin Struct Biol. 2001;11(5):623-628.
9. van de Weert M, Andersen MB, Frokjaer S. Complex coacervation of lysozyme and heparin: complex characterization and protein stability. Pharm Res. 2004;21(12):2354-2359.
10. Rossmann P, Matousovic K, Horacek V. Protamine-heparin aggregates. Their fine structure, histochemistry, and renal deposition. Virchows Arch B Cell Pathol. 1982;40(1):81-98.
11. Lyapina LA, Ul'yanov AM. Formation of complexes of heparin with proteins and its physiological role. II. Hum Physiol. 1979;4(2):239-248.
12. Boschetti E, Girot P, Secheresse JP, Saint Blancard J. Study of the molecular interaction between lysozyme and heparin and application in affinity chromatography. J Chromatogr. 1981;210:469-475.
13. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol. 2000;164(3):2978-2986.
14. Fischer A. Die Bindung von Heparin an Eiweiss. Biochem Z. 1935;278:133.
15. Villanueva GB, Danishefsky I. Evidence for a heparin-induced conformational change on antithrombin III. Biochem Biophys Res Commun. 1977;74(2):803-809.
16. Volkin DB, Tsai PK, Dabora JM, et al. Physical stabilization of acidic fibroblast growth factor by polyanions. Arch Biochem Biophys. 1993;300(1):30-41.
17. Lookene A, Chevreuil O, Ostergaard P, Olivecrona G. Interaction of lipoprotein lipase with heparin fragments and with heparan sulfate: stoichiometry, stabilization, and kinetics. Biochemistry. 1996;35(37):12155- 12163.
18. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007;446(7139):1030-1037.
19. Suvarna S, Qi R, Hollingsworth JW, Arepally GM. Platelet Factor 4 (PF4)-Heparin complexes Trigger Immune Responses independently of the MyD88 Pathway. Br J Haematol. 2008;142(4):671-673.
20. Suvarna S, Rauova L, McCracken EKE, et al. PF4/heparin complexes are T cell-dependent antigens. Blood. 2005;106(3):929-931.
21. Balhorn R. The protamine family of sperm nuclear proteins. Genome Biol. 2007;8(9):227.
22. Pascu C, Ljungh A, Wadstrom T. Staphylococci bind heparin-binding host growth factors. Curr Microbiol. 1996;32(4):201-207.
23. Blake CC, Koenig DF, Mair GA, North AC, Phillips DC, Sarma VR. Structure of hen egg-white lysozyme. A three-dimensional Fourier synthesis at 2 Angstrom resolution. Nature. 1965;206(986):757-761.
24. McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007;27(5):687-690.
25. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl): 141S-159S. (Pubitemid 351892966)
26. Pouplard C, Amiral J, Borg JY, Vissac AM, Delahousse B, Gruel Y. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol. 1997;99(2):273-280.
27. Warkentin TE. Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies-distinguishing "signal" from "noise." Thromb Haemost. 2008;100(4):523-524.
28. Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 2008;100(4):678-684.
29. Whitlatch NL, Kong DF, Metjian AD, Arepally GM, Ortel TL. Validation of the high-heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood. 2010:116 (10):1761-1766.
30. Reis e Sousa C, Germain RN. Analysis of adjuvant function by direct visualization of antigen presentation in vivo: endotoxin promotes accumulation of antigen-bearing dendritic cells in the T-cell areas of lymphoid tissue. J Immunol. 1999;162(11):6552-6561.
31. Bacsi S, De Palma R, Visentin GP, Gorski J, Aster RH. Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia/thrombosis. Blood. 1999;94(1):208-215.
32. Bacsi S, Geoffrey R, Visentin G, De Palma R, Aster R, Gorski J. Identification of T cells responding to a self-protein modified by an external agent. Hum Immunol. 2001;62(2):113-124.
33. Selleng K, Schutt A, Selleng S, Warkentin TE, Greinacher A. Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. Transfusion. 2010;50(1):32-39.
34. Warkentin TE, Sheppard J-AI, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood. 2009;113(20):4963-4969.
35. Keeler JF, Hansbro SD, Shah MV. Protamine - what dose? J Cardiothorac Anesth. 1990;4(6 suppl 3):41S-41S.
36. Fitzgerald DJ, Patel A, Body SC, Garvin S. The relationship between heparin level and activated clotting time in the adult cardiac surgery population. Perfusion. 2009;24(2):93-96.
37. Butterworth J, Lin YA, Prielipp RC, Bennett J, Hammon JW, James RL. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg. 2002;74(3):1589-1595.
38. Bical OM, Fromes Y, Gaillard D, et al. Comparison of the inflammatory response between miniaturized and standard CPB circuits in aortic valve surgery. Eur J Cardiothorac Surg. 2006;29(5):699-702.
39. Welsby IJ, Newman MF, Phillips-Bute B, Messier RH, Kakkis ED, Stafford-Smith M. Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery. Anesthesiol. 2005;102(2):308-314.
40. Vézina D, Sheridan P, Blain R, Roberts KD, Bleau G. Safety of protamine sulfate administration in vasectomized men. Contraception. 1990;41(6):605-616.
41. Nell LJ, Thomas JW. Frequency and specificity of protamine antibodies in diabetic and control subjects. Diabetes. 1988;37(2):172-176.
42. Weiss ME, Nyhan D, Peng ZK, et al. Association of protamine IgE and IgG antibodies with lifethreatening reactions to intravenous protamine. N Engl J Med. 1989;320(14):886-892.
43. Adourian U, Shampaine EL, Hirshman CA, Fuchs E, Adkinson NF Jr. High-titer protamine-specific IgG antibody associated with anaphylaxis: report of a case and quantitative analysis of antibody in vasectomized men. Anesthesiol. 1993;78(2):368-371.
44. Amiral JJ, Vissac AM. Pseudo-HIT associated with antibodies to protamine sulfate. J Eur J Thromb Haemost. 2009;5(S2). Abstract PP-MO-697.
45. Schindewolf M, Schwaner S, Wolter M, et al. Incidence and causes of heparin-induced skin lesions. Can Med Assoc J. 2009;181(8):477-481.
46. Kimmel SE, Sekeres MA, Berlin JA, Ellison N, DiSesa VJ, Strom BL. Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. J Am Coll Cardiol. 1998;32(7):1916-1922.